Table 1.
Baseline Demographic and Clinical Data and Statistics
| Healthy Controls (N = 242) | CHR (N = 609) | t/χ2 | P Value | |
|---|---|---|---|---|
| Age, y | 19.77±4.80 | 18.55±4.35 | 3.42 | <.001 |
| Education, y | 12.67±3.64 | 11.27±2.83 | 5.35 | <.001 |
| Sex, N male (%) | 126 (52.1) | 352 (57.8) | 2.31 | .13 |
| Race, N Caucasian (%) | 133 (54.96) | 352 (57.80) | 0.570 | .450 |
| Premorbid IQ | 108.30±16.30 | 105.15±16.56 | 2.50 | .013 |
| Current IQ | 111.14±14.03 | 103.83±15.09 | 6.48 | <.001 |
| Scale of prodromal symptoms | ||||
| Positive | 1.02±1.63 | 11.94±3.86 | −57.90 | <.001 |
| Negative | 1.46±2.30 | 11.83±5.96 | −36.44 | <.001 |
| Disorganized | 0.63±1.17 | 5.16±3.08 | −30.88 | <.001 |
| General | 1.30±2.16 | 9.25±4.22 | −35.90 | <.001 |
| GAF score | 83.41±10.76 | 48.38±10.74 | 42.83 | <.001 |
| Global Functioning: Social Scale | 8.87±0.928 | 6.22±1.54 | 30.61 | <.001 |
| Global Functioning: Role Scale | 8.53±1.39 | 5.97±2.16 | 20.46 | <.001 |
| Baseline medicationa | ||||
| No medication | — | 372 (61.1) | — | — |
| Anti-psychotics | — | 120 (19.7) | — | — |
| Anti-depressants | — | 156 (25.6) | — | — |
| Anxiolytic | — | 42 (6.9) | — | — |
| Mood stabilizer | — | 21 (3.4) | — | — |
Note: CHR, Clinical High-Risk; GAF, Global Assessment of Functioning Scale.
aFive CHR subjects were missing medication information for the baseline testing.